Herantis Pharma plc, of Helsinki, Finland, started recruitment for its phase I testing CDNF in 18 patients with Parkinson's disease. The trial will compare the safety and efficacy of CDNF, a natural protein with neuroprotective and neurorestorative properties, to placebo.